FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill
Executive Summary
FDA and CMS are directed to jointly develop guidelines on clinical studies relating to cancer care and treatment biomarkers in legislation (S. 717) introduced by Sens. Ted Kennedy, D-Mass., and Kay Bailey Hutchinson, R-Texas, on March 26